We are currently testing CNP520 in the Generation Program (Lopez Lopez et al, 2017), a pivotal program designed to assess efficacy and safety in an as yet cognitively unimpaired population at increased risk for developing clinical symptoms of AD based on their age and APOE4 genotype (NCT02565511 and NCT03131453). This evidence concerns the gene APOE and Alzheimer disease.